Academic

Academic Work & Publications

Articles, conference papers, book chapters, clinical trials and awards.

Academic profile

Academic identity

Information on the academic and clinical experience of Assoc. Prof. Dr. Ali Oğul, including areas of work, academic identity and current publication records, is updated regularly. The list below is compiled from the records of the Mersin University Academic Staff Information System (APBS); for the most current full list, see the ORCID and APBS profiles.

  • 46Articles
  • 26Conference papers
  • 9Clinical trials and projects
  • 5Book chapters

Compiled from Mersin University APBS records (updated: 01.09.2026).

Articles 46

Articles published in international and national peer-reviewed journals, ordered by year. DOI links lead to the source of the publication.

2026

  1. 2026

    Awareness and attitudes toward cytoreductive surgery and hyperthermic intraperitoneal chemotherapy among surgical and medical oncologists

    Scientific Reports SCI-Expanded · Q1

    DOI: 10.1038/s41598-026-43750-y
  2. 2026

    First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score

    Medicina (Lithuania), 62(8), 1470

    DOI: 10.3390/medicina62081470
  3. 2026

    Prognostic significance of PET/CT-derived metabolic heterogeneity indices in wild-type metastatic colorectal cancer

    Cukurova Medical Journal, 51(1), 206–216

    DOI: 10.17826/cumj.1839084

2025

  1. 2025

    Prognostic Value of Metabolic Tumor Volume and Heterogeneity Index in Diffuse Large B-Cell Lymphoma

    Medicina (Lithuania), 61(8), 1370 SCI-Expanded · Q1

    DOI: 10.3390/medicina61081370
  2. 2025

    Importance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography heterogeneity indices in non-small cell lung cancer

    Revista da Associação Médica Brasileira, 71(5) SCI-Expanded · Q2

    DOI: 10.1590/1806-9282.20241408
  3. 2025

    Prognostic value of inflammatory-nutritional indexes and HALP score in advanced stage NSCLC treated with first-line TKI

    Biomarkers in Medicine, 19(17), 1–9 SCI-Expanded · Q3

    DOI: 10.1080/17520363.2025.2560797
  4. 2025

    Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

    Scientific Reports, 15(1), 3200 SCI-Expanded · Q1

    DOI: 10.1038/s41598-025-87553-z
  5. 2025

    Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

    Current Oncology, 32(11), 639–639 SCI-Expanded · Q2

    DOI: 10.3390/curroncol32110639

2023

  1. 2023

    A new prognostic index associated with pathological complete response in rectal cancer

    Cukurova Medical Journal, 48(2), 575–582 ESCI: Emerging Sources Citation Index

    DOI: 10.17826/cumj.1279880
  2. 2023

    Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer

    Revista da Associação Médica Brasileira, 69(1), 153–158 SCI-Expanded

    DOI: 10.1590/1806-9282.20221123
  3. 2023

    Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer

    Journal of Cancer Research and Therapeutics, 20(1), 285–288 SCI-Expanded

    DOI: 10.4103/jcrt.jcrt_1858_22
  4. 2023

    Relationship of the Hemoglobin/Red Cell Distribution Width Ratio and Inflammatory Biomarkers with Prognosis in Nasopharyngeal Cancer

    Eurasian Journal of Medical Investigation EBSCO

    DOI: 10.14744/ejmi.2023.30252
  5. 2023

    Brigatinib-associated autoimmune hepatitis: A case report

    Journal of Oncology Pharmacy Practice, 32(4), 754–756 SCI-Expanded

    DOI: 10.1177/10781552231171322

2022

  1. 2022

    Panitumumab Associated Acute Pancreatitis

    Journal of Oncology Pharmacy Practice, 28(5), 1207–1208 SCI-Expanded

    DOI: 10.1177/10781552221073997
  2. 2022

    Sarcoma – correlation between CD73 and PD-L1 and their relationship with prognosis

    Polish Journal of Pathology, 73(4), 338–342 SCI-Expanded · Q4

    DOI: 10.5114/pjp.2022.125537

2021

  1. 2021

    The effect of preferentially expressed antigen in melanoma (PRAME) expression status on survival in stage II and stage III colon cancer

    Journal of BUON, 26(3), 1–10 SCI-Expanded · Q4

  2. 2021

    Carotid-femoral pulse wave velocity is significantly increased in newly diagnosed hypertensive patients with primary hyperparathyroidism and significantly related with serum calcium level

    Journal of Ultrasound, 24(4), 439–446 Emerging Sources Citation Index (ESCI)

    DOI: 10.1007/s40477-020-00512-4
  3. 2021

    Abiraterone Acetate–Associated Acute Pancreatitis: A Case Report

    American Journal of Therapeutics, 30(3), e296–e298 SCI-Expanded

    DOI: 10.1097/mjt.0000000000001381
  4. 2021

    The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen

    Journal of Gastrointestinal Cancer, 52(1), 249–255 Emerging Sources Citation Index

    DOI: 10.1007/s12029-020-00396-x
  5. 2021

    Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers

    Journal of Gastrointestinal Cancer, 52(1), 294–299 Emerging Sources Citation Index

    DOI: 10.1007/s12029-020-00428-6

2020

  1. 2020

    New-Generation Anaplastic Lymphoma Kinase Inhibitor Experience in a Case With Non–Small Cell Lung Cancer: High Efficacy but Unexpected Toxicity

    American Journal of Therapeutics, 28(6), e799–e801 SCI-Expanded

    DOI: 10.1097/mjt.0000000000001115
  2. 2020

    Prognostic role of inflammatory markers in hepatocellular cancer patients receiving sorafenib therapy

    Medical Science and Discovery, 7(5), 475–481 INDEX COPERNİCUS

    DOI: 10.36472/msd.v7i5.374
  3. 2020

    Dynamic prognostic nutritional index could be a novel predictor of survival in lung cancer patients treated with nivolumab

    Annals of Clinical and Analytical Medicine, 11(Suppl_1), 1–6 Emerging Sources Citation Index (ESCI)

    DOI: 10.4328/acam20025
  4. 2020

    Inflammatory markers and clinical factors which affecting the survival in metastatic renal cell carcinoma

    Medical Science and Discovery, 7(4), 459–465 INDEX COPERNİCUS

    DOI: 10.36472/msd.v7i4.370
  5. 2020

    Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases

    Turkish Journal of Hematology, 37(4), 220–225 SCI-Expanded

  6. 2020

    Factors predicting prognosis of oncology patients followed in the intensive care unit

    Cukurova Medical Journal, 45(4), 1267–1275 Emerging Sources Citation Index (ESCI)

    DOI: 10.17826/cumj.789199
  7. 2020

    Dose-Adjusted R-EPOCH Therapy for Aggressive Lymphoma: A single center experience

    Medical Science and Discovery, 7(11), 691–695 INDEX COPERNİCUS

    DOI: 10.36472/msd.v7i11.438
  8. 2020

    Efficacy of Prephase Treatment for the Prevention of Tumor Lysis Syndrome in Lymphoma Cases with High Tumor Burden: A Cross-Sectional Study

    International Journal of Hematology and Oncology, 30(2), 87–93 SCI-Expanded

    DOI: 10.4999/uhod.204157
  9. 2020

    Prognostic signficance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer

    Journal of BUON, 25(1), 159–167 SCI-Expanded

  10. 2020

    Metastatik Meme Kanserli Hastaların Klinik Özellikleri ve Tedavi Sonuçları: Tek Merkez Deneyimi

    Anadolu Kliniği Tıp Bilimleri Dergisi, 25(2), 75–80 TR DİZİN

    DOI: 10.21673/anadoluklin.641856
  11. 2020

    Inflammatory Markers Predicting Pathological Complete Response in Cases with Breast Cancer Treated by Neoadjuvant Chemotherapy

    European Journal of Breast Health, 16(4), 229–234 TR DİZİN

    DOI: 10.5152/ejbh.2020.5556
  12. 2020

    LENFOMA HASTALARINDA HEPATİT B VE C PREVALANSININ DEĞERLENDİRİLMESİ

    Namık Kemal Tıp Dergisi, 8(1), 48–51 TR DİZİN

    DOI: 10.37696/nkmj.632911
  13. 2020

    Predictive Biomarkers in Late Onset Neutropenia (LON) Associated with Rituximab

    Eurasian Journal of Medical Investigation, 4(4), 428–432 TR DİZİN

    DOI: 10.14744/ejmi.2020.55639

2019

  1. 2019

    Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study

    Cancer Management and Research, 11(23), 3445–3453 SCI-Expanded

    DOI: 10.2147/cmar.s191199
  2. 2019

    Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC)

    International Journal of Clinical Oncology, 24(2), 168–178 SCI-Expanded

    DOI: 10.1007/s10147-018-1338-8
  3. 2019

    Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small cell lung cancer: Single center experience from Turkey

    Balkan Journal of Medical Genetics, 22(2), 17–24 SCI-Expanded

    DOI: 10.2478/bjmg-2019-0016
  4. 2019

    Atypical Radiologic Image Characterized by Cavitary Lung Lesions in a Case of Hodgkin Lymphoma

    Turkish Journal of Hematology, 36(1), 60–61 SCI-Expanded

    DOI: 10.4274/tjh.galenos.2018.2018.0115
  5. 2019

    Prognostic significance of dynamic inflammatory indexes in cases renal cell cancer treated by tyrosine kinase inhibitor (TKI)

    Acta Oncologica Turcica, 52(3), 372–378 TR DİZİN

    DOI: 10.5505/aot.2019.08760
  6. 2019

    LONG-TERM OUTCOME OF SOFT TISSUE SARCOMAS TREATED WITH MESNA-DOXORUBICIN-IFOSFAMID-DACARBAZINE REGIMEN (MAID): A RETROSPECTIVE STUDY FROM A SINGE INSTITUTION

    Namık Kemal Tıp Dergisi, 7(3), 271–278 TR DİZİN

  7. 2019

    Clinical Significance of PRAME and PDL-1 Expression in Colon Cancer

    3(1), 47–47

    DOI: 10.14744/ejmo.2019.2019

2018

  1. 2018

    Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and rewiev of the literature

    Journal of Oncological Sciences (JOS), 4(1), 56–59 INDEX COPERNİCUS

    DOI: 10.1016/j.jons.2018.03.002
  2. 2018

    Myeloid Neoplasia and Lymphoblastic Lymphoma with Eosinophilia After Radioactive Iodine: A Case Report

    Balkan Medical Journal, 35(2), 199–202 SCI-Expanded

    DOI: 10.4274/balkanmedj.2017.0600
  3. 2018

    G-CSF related hemophagocytosıs in a case with lymhphoma

    Clinical Research and Trials, 4(1), 1–2 Not indexed

    DOI: 10.15761/crt.1000203
  4. 2018

    Metastatic Renal Cell Carcinoma Case Report Undergoing Multiple Treatment Options and Review of Literature

    Eurasian Journal of Medical Investigation, 2(2), 101–103 Index Copernicus

    DOI: 10.14744/ejmi.2018.76376

2017

  1. 2017

    The Importance of Parameters: MPV, MPV/Thrombocyte Ratio and Neutrophil/Lymphocyte Ratio in Sorafenib Treatment Response of Patients with Hepatocellular Cancer

    Journal of Gastrointestinal Cancer, 48(3), 286–287

    DOI: 10.1007/s12029-017-9970-5

2016

  1. 2016

    Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma

    Annals of Hematology, 95(1), 145–146 SCI-Expanded

    DOI: 10.1007/s00277-015-2493-x

Conference papers 26

Papers presented at 6 international and 20 national congresses or symposia.

  1. 2024

    Lenvatinib İlişkili Nöropati: Bir Olgu Sunumu ve Literatür Taraması

    8.Uluslararası Sağlık Bilimleri ve Aile Hekimliği Kongresi (14.03.2024 – )

    Ali Oğul · Abstract · Oral presentation

  2. 2021

    HER2 POZİTİF MEME KANSERİNDE NEOADJUVANT TEDAVİYE PATOLOJİK YANITI BELİRLEYEN KLİNİKOPATOLOJİK FAKTÖRLER

    4. GENÇLERLE ONKOLOJİYE BAKIŞ KONGRESİ (12.02.2021 – 14.02.2021)

    Ali Oğul, Mahmut Büyükşimşek · Abstract · Oral presentation

  3. 2020

    Malign Melanom Hastalarında D Vitamini Düzeylerinin İncelenmesi

    3rd International Hippocrates Congress on Medical and Health Sciences (06.03.2020 – 07.03.2020)

    Ali Oğul, Mahmut Büyükşimşek · Abstract · Oral presentation

  4. 2020

    Ağız Ve Orofarenks Yerleşimli Non-Hodgkin Lenfomada Tek Merkez Deneyimi

    19th International Eastern Mediterranean Family Medicine Congress (17.09.2020 – 20.09.2020)

    Ali Oğul, Mahmut Büyükşimşek · Abstract · Oral presentation

  5. 2020

    Neoadjuvan Kemoterapi Alan Meme Kanseri Hastalarında EZH2 ve MUC-1 Ekspresyonlarının Patolojik Tam Yanıt ile İlişkisi

    4. Ulusal İmmünoterapi ve Onkoloji Kongresi (29.10.2020 – 01.11.2020)

    Mahmut Büyükşimşek, Ali Oğul, Semra Paydaş, Özge Yaprak, Suzan Zorludemir, Melek Ergin · Abstract · Oral presentation

  6. 2020

    BAĞ VE YUMUŞAK DOKU SARKOMLARINDA TEK MERKEZ DENEYİMİ

    3. GENÇLERLE ONKOLOJİYE BAKIŞ KONGRESİ (13.02.2020 – 16.02.2020)

    Ali Oğul, Mahmut Büyükşimşek · Abstract · Oral presentation

  7. 2019

    Evre II ve Evre III Kolon Kanseri Hastalarında D Vitamini Düzeyinin İncelenmesi

    V. International Congress on Natural and Health Sciences (13.12.2019 – 15.12.2019)

    Ali Oğul · Abstract · Oral presentation

  8. 2019

    YENİ TANI ALMIŞ KANSER HASTALARINA YÖNELİK BİLGİLENDİRME SÜRECİ UYGULAMALARI

    International Hippocrates Congress on Medical and Health Sciences (01.03.2019 – 03.03.2019)

    Ali Oğul · Abstract · Oral presentation

  9. 2019

    Malignitesi olan hastalarda ilaç yan etkileri ve tiroid fonksiyonları

    18th International Eastern Mediterranean Family Medicine Congress (25.04.2019 – 28.04.2019)

    Mahmut Büyükşimşek, Hilmi Erdem Sümbül, Ali Oğul · Abstract · Oral presentation

  10. 2019

    LOKAL İLERİ VE METASTATİK MUKOEPİDERMOİD KARSİNOMDA TEK MERKEZ DENEYİMİ

    VI. Nadir Tümörler Sempozyumu (22.02.2019 – 24.02.2019)

    Ali Oğul, Semra Paydaş · Abstract · Oral presentation

  11. 2019

    LORLATINIB EXPERIENCE IN A CASE WITH NON- SMALL CELL LUNG CANCER (NSCLC): HIGH EFFICACY BUT UNEXPECTED HIGH TOXICITY

    23. ULUSAL KANSER KONGRESİ (17.04.2019 – 21.04.2019)

    Mahmut Büyükşimşek, Semra Paydaş, Abdullah Evren Yetişir, Cem Mirili, Ali Oğul, Servet Başdoğan · Abstract · Poster

  12. 2018

    AKCİĞER ADENOKARSİNOMUNDA C-MET AMPLİFİKASYONU VE KRİZOTİNİB TEDAVİSİ; OLGU SUNUMU

    7. Türk Tıbbi Onkoloji Kongresi (21.03.2018 – 25.03.2018)

    Abdullah Evren Yetişir, Semra Paydaş, Mahmut Büyükşimşek, Ali Oğul, Mert Tohumcuoğlu · Abstract · Poster

  13. 2018

    KEMOTERAPİ İLİŞKİLİ PELLAGRA

    7. Türk Tıbbi Onkoloji Kongresi (21.03.2018 – 25.03.2018)

    Ali Oğul, Semra Paydaş, Cem Mirili, Mahmut Büyükşimşek, Abdullah Evren Yetişir, Mert Tohumcuoğlu, Bilgin Karaalioğlu · Abstract · Poster

  14. 2018

    NİVOLUMAB ERKEN ERİŞİM PROGRAMI: UZUN DÖNEM TAKİP VERİLERİ

    7. Türk Tıbbi Onkoloji Kongresi (21.03.2018 – 25.03.2018)

    Cem Mirili, Semra Paydaş, İsa Burak Güney, Ali Oğul, Serkan Gökçay, Mahmut Büyükşimşek, Abdullah Evren Yetişir, Mert Tohumcuoğlu, Bilgin Karaalioğlu · Abstract · Poster

  15. 2018

    G-CSF RELATED HEMOPHAGOCYTOSIS IN A CASE WITH LYMHPHOMA

    7. Türk Tıbbi Onkoloji Kongresi (21.03.2018 – 25.03.2018)

    Bilgin Karaalioğlu, Semra Paydaş, Abdullah Evren Yetişir, Cem Mirili, Elçin İsmayilov, Mahmut Büyükşimşek, Ali Oğul, Emine Kılıç Bağır, Melek Ergin · Abstract · Poster

  16. 2018

    KÜÇÜK HÜCRELİ AKCİĞER KANSERİNDE KHAK NÖTROFİL LENFOSİT ORANI NLO İLE PET CT’DE SAPTANAN METABOLİK PARAMETRELERİNİN PET CT MP PROGNOSTİK ÖNEMİ VE NLO İLE PET CT MP İLİŞKİSİ

    7. Türk Tıbbi Onkoloji Kongresi (21.03.2018 – 25.03.2018)

    Cem Mirili, Semra Paydaş, İsa Burak Güney, Gülşah Seydaoğlu, Tuba Korkmaz Kapukaya, Ali Oğul, Serkan Gökçay · Abstract · Oral presentation

  17. 2018

    EDİNSEL İMMÜN YETMEZLİKLİ BİR OLGUDA KAPOSİ SARKOMUNUN EŞLİK ETTİĞİ TAFRO SENDROMU

    7. Türk Tıbbi Onkoloji Kongresi (21.03.2018 – 25.03.2018)

    Mert Tohumcuoğlu, Semra Paydaş, Ali Oğul, Mahmut Büyükşimşek, Abdullah Evren Yetişir, Behice Kurtaran, Melek Ergin, Cem Mirili, Bilgin Karaalioğlu · Abstract · Poster

  18. 2017

    Prephase tedavinin yüksek tümör yükü olan lenfomalı hastalarda tümör lizis sendromunu önlemede etkinliği

    Ulusal İmmünoterapi ve Onkoloji kongresi (25.10.2017 – 29.10.2017)

    Ali Oğul, Semra Paydaş, Abdullah Evren Yetişir, Cem Mirili, Mahmut Büyükşimşek, Serkan Gökçay · Abstract · Poster

  19. 2017

    Paratiroid karsinomlu, hiperkalsemik hastada perkutan alkol enjeksiyonu seçeneği

    Ulusal İmmünoterapi ve Onkoloji kongresi (25.10.2017 – 29.10.2017)

    Ali Oğul, Semra Paydaş, Abdullah Evren Yetişir, Mahmut Büyükşimşek, Cem Mirili · Abstract · Poster

  20. 2017

    ANAPLASTİK PLAZMA HÜCRE NEOPLAZİSİ ŞEKLİNDE PREZENTE OLAN POEMS SENDROMU

    22. ULUSAL KANSER KONGRESİ (19.04.2017 – 23.04.2017)

    Mahmut Büyükşimşek, Abdullah Evren Yetişir, Ali Oğul, Serkan Gökçay, Cem Mirili, Berksoy Şahin · Abstract · Poster

  21. 2017

    İNGUNİAL BÖLGEDE İNFLAMATUAR MYOFİBROBLASTİK TÜMÖR; OLGU SUNUMU

    22. ULUSAL KANSER KONGRESİ (19.04.2017 – 23.04.2017)

    Abdullah Evren Yetişir, Mahmut Büyükşimşek, Ali Oğul, Serkan Gökçay, Cem Mirili, Berksoy Şahin · Abstract · Poster

  22. 2017

    Renal Primitif Nöroektodermal Tümör; Olgu Sunumu

    Ulusal İmmünoterapi ve Onkoloji kongresi (25.10.2017 – 29.10.2017)

    Abdullah Evren Yetişir, Semra Paydaş, Mahmut Büyükşimşek, Ali Oğul · Abstract · Poster

  23. 2017

    RAI TEDAVİSİ SONRASI GELİŞEN EOZİNOFİLİK MYELOİD NEOPLAZİ VE LENFOBLASTİK LENFOMA BİRLİKTELİĞİ

    22. ULUSAL KANSER KONGRESİ (19.04.2017 – 23.04.2017)

    Mahmut Büyükşimşek, Abdullah Evren Yetişir, Ali Oğul, Serkan Gökçay, Cem Mirili, Semra Paydaş · Abstract · Poster

  24. 2017

    The Importance of Parameters: MPV, MPV/Thrombocyte Ratio and Neutrophil/Lymphocyte Ratio in Sorafenib Treatment Response of Patients with Hepatocellular Cancer

    1. Çukurova Hepatoselüler Karsinoma Sempozyumu (10.02.2017 – 11.02.2017)

    Ali Oğul, Berksoy Şahin, Ferit Kuşcu, Onur Taktakoğlu, Abdullah Evren Yetişir, Mahmut Büyükşimşek, Cem Mirili, Serkan Gökçay, Mehmet Gökhan Gök, Pınar Kum · Abstract · Oral presentation

  25. 2017

    REAL WORLD EXPERİENCE: NİVOLUMAB EXPANDED ACCESS PROGRAM IN TURKEY

    22. ULUSAL KANSER KONGRESİ (19.04.2017 – 23.04.2017)

    Cem Mirili, Semra Paydaş, Serkan Gökçay, Ali Oğul, Mahmut Büyükşimşek, Abdullah Evren Yetişir · Abstract · Poster

  26. 2017

    GEBELİKLE İLİŞKİSİZ GESTASYONEL TROFOBLASTİK TÜMÖR:VAKA SUNUMU

    22. ULUSAL KANSER KONGRESİ (19.04.2017 – 23.04.2017)

    Serkan Gökçay, Berksoy Şahin, Ali Oğul, Cem Mirili, Mahmut Büyükşimşek, Abdullah Evren Yetişir · Abstract · Poster

Book chapters 5

  1. 2021

    Gebelikte Meme Kanserinde Anti-Her2 Tedavilerinin Kullanımı

    Gebelikte Onkolojik Yaklaşımlar · Akademisyen Yayınevi

  2. 2020

    Hedgehog Yolağı İnhibisyonunu Sağlayan İlaçlar ve Etki Mekanizmaları

    Onkolojide Moleküler Hedefli Tedaviler · Akademisyen Yayınevi

  3. 2019

    Timoma ve Timik Karsinomda Sistemik Tedaviler

    Toraks Tümörleri · Akademisyen Yayınevi

  4. 2019

    Malign Plevral Effüzyonların Yönetimi

    Onkolojide Özel Konular · Akademisyen Yayınevi

  5. 2018

    Hepatoselüler Kanser Tedavisinde Güncel Yaklaşım

    Akademisyen Yayınevi Bilimsel Araştırmalar Kitabı

Awards 3

  • 2020Second Prize for Research Article, National Lung Health Congress (Turkey)Akciğer Sağlığı ve Yoğun Bakım Derneği
  • 2017First Prize, Dr. İbrahim Türker Research Awards, National Immunotherapy and Oncology Congress (Turkey)Onkoloji ve İmmünoterapi Derneği
  • 2016Abstract Award, 3rd National Congress of Immuno-Oncology and Targeted Cancer Therapies (Turkey)İmmüno-Onkoloji Derneği

Clinical trials and projects 9

Investigator in 8 international multicentre clinical trials and principal investigator in 1 national project.

  1. 2024 –

    DESTINY-Gastric04: trastuzumab deruxtecan in HER2-positive metastatic or unresectable gastric / gastroesophageal junction adenocarcinoma, phase 3

    International · Investigator · Ongoing

  2. 2024 –

    Comparison of HD204 with reference bevacizumab in metastatic or recurrent non-squamous non-small cell lung cancer, phase 3 equivalence study

    International · Investigator · Ongoing

  3. 2024 –

    Zimberelimab (AB122) in first-line treatment of PD-L1-positive non-small cell lung cancer, phase 3

    International · Investigator · Ongoing

  4. 2024

    Relationship between eIF5B expression and survival in glioblastoma patients who received adjuvant temozolomide and radiotherapy

    National · Principal investigator

  5. 2024–2025

    Long-term follow-up study for volunteers who took part in bintrafusp alfa (M7824) clinical trials

    International · Investigator · Completed

  6. 2017–2025

    Study comparing REGN2810 (anti-PD-1) with platinum-based chemotherapy in metastatic non-small cell lung cancer, phase 3

    International · Investigator · Completed

  7. 2017 –

    GAMMA-1: first-line andecaliximab and mFOLFOX6 in advanced gastric / gastroesophageal junction adenocarcinoma, phase 3

    International · Investigator

  8. 2015 –

    Nab-paclitaxel and atezolizumab in previously untreated triple-negative metastatic breast cancer, phase III (WO29522)

    International · Investigator

  9. 2015–2021

    PACIFIC: MEDI4736 (durvalumab) after chemoradiotherapy in stage III unresectable non-small cell lung cancer, phase III

    International · Investigator · Completed

Courses and certificates 7

  1. 2019

    Medical Oncology Proficiency Certificate

    Turkish Society of Medical Oncology · Antalya

  2. 2018

    Diagnosis, treatment and multidisciplinary management in metastatic colorectal and breast cancer

    Oldenburg (international)

  3. 2018

    Update course on gastrointestinal system cancers

    TTOD Postgraduate Update Courses · Ankara

  4. 2017

    Applied biostatistics training with IBM SPSS

    Adana

  5. 2016

    Update course on head and neck and central nervous system cancers

    TTOD Postgraduate Update Courses · İzmir

  6. 2015

    Update course on breast cancer

    TTOD Postgraduate Update Courses · Istanbul

  7. 2013

    Applied training programme on preventing invasive device-associated infections

    Çukurova University Balcalı Hospital · Adana

Memberships and thesis supervision

  1. 2015 –

    Turkish Society of Medical Oncology

    Member · Scientific society

  2. 2024

    Effect of intratumoral heterogeneity index on survival in wild-type metastatic colon adenocarcinoma

    Medical specialty thesis supervision · SBÜ Adana Faculty of Medicine, Department of Internal Medicine

Sources: Mersin University APBS · ORCID

Contact

Get in touch for appointments and information

To make an appointment, you can send a WhatsApp message or call +90 530 250 54 85.

You can send your request for a second opinion and your current pathology, imaging and discharge reports via WhatsApp; the evaluation takes place face to face in the outpatient clinic. Process and required documents

Mersin University Faculty of Medicine Oncology HospitalÇiftlikköy Mah. MEÜ Çiftlikköy Campus, 33110 Yenişehir/Mersin, TurkeyGet directions

The content of this website is for general information only and does not replace an individual medical assessment, diagnosis or treatment recommendation.